SLU-PP-332
Pan-ERR agonist (small molecule)
An estrogen-related receptor agonist studied as an exercise mimetic for oxidative metabolism.
How it works
SLU-PP-332 is not a peptide. It is a small synthetic molecule (CAS 2172651-38-1) that acts as a pan-agonist at the estrogen-related receptors ERR alpha, ERR beta and ERR gamma. These receptors are orphan nuclear receptors, meaning they act as transcription factors inside the cell nucleus rather than as surface receptors that a peptide would bind.
The ERR family sits at the center of the transcriptional program that endurance exercise normally switches on. When activated, these receptors upregulate genes governing mitochondrial biogenesis, oxidative phosphorylation and fatty acid oxidation, which is why researchers describe the compound as an exercise mimetic tool rather than a hormone analog.
In published rodent work the compound shifted skeletal muscle toward a more oxidative fiber profile, increased whole body energy expenditure and increased reliance on fat as a fuel substrate, with running capacity improving without a change in food intake. Because the mechanism is transcriptional, effects in that literature accumulate over days of repeated administration rather than appearing acutely.
All published data is preclinical. There are no human trials, no established human range and no clinical safety profile, so it is used strictly as an in vitro and animal research chemical.
What research has shown
Mouse studies report increased running capacity, higher energy expenditure and reduced fat mass without change in food intake.
Reported ranges in the literature
Low end
5 mg/kg daily in animal work
Optimal
Animal data only, no established human range
High end
50 mg/kg daily in rodent studies
Frequency reported in the literature: Daily in reported animal protocols. Note: Preclinical only. No human trial data is published.
Protocol duration and pairing
Typical study duration
Preclinical work uses 2 to 8 week windows.
Best paired with
Exercise mimetic studied alongside other oxidative metabolism compounds.
Frequently asked questions
What is SLU-PP-332?
SLU-PP-332 is a small molecule pan-agonist of the estrogen-related receptors ERR alpha, beta and gamma, CAS 2172651-38-1. It is a research chemical, not a peptide, and is studied as an exercise mimetic tool compound.
Is SLU-PP-332 a peptide?
No. It is a synthetic small molecule that acts on nuclear receptors. It is listed alongside peptides here because it appears in the same metabolic research protocols, but it is chemically a different class of compound.
What does the research show?
Rodent studies report increased running capacity, higher energy expenditure, increased fatty acid oxidation and reduced fat mass without a change in food intake. Findings are preclinical only.
What is it studied alongside?
It appears in the literature next to other oxidative metabolism tool compounds such as AICAR, which activates AMPK, and MOTS-c, a mitochondrial derived peptide. Those pathways converge on the same mitochondrial gene program.
How long are research blocks typically?
Preclinical work generally uses 2 to 8 week administration windows, which is the interval over which transcriptional changes in mitochondrial gene expression are measured.
Does it require reconstitution?
It is supplied as a solid rather than a lyophilized peptide, so handling in the literature follows small molecule solubility practice rather than the bacteriostatic water reconstitution used for peptide vials.
Related compounds
Further reading
Research use only
All content on this page is general reference information for laboratory research contexts. It is not medical advice, is not intended to direct human use, and does not replace guidance from a licensed healthcare professional. Not for human consumption. Must be 18+.